Author(s)
Ronald Preblick, MPH, PharmD, Bayer HealthCare Pharmaceuticals Inc. Health Economics, Outcome and Reimbursement (HEOR)1, Doug Jeffery, MD, PhD, Professor2, Stephen Kirzinger, MD, MS Program Director/Assistant Professor3, June Halper, MSCN, ANP, FAAN, Executive Director4, Yi Jia Bi, MD, MS, Bayer HealthCare Pharmaceuticals Inc. Health Economics, Outcome and Reimbursement (HEOR)1, Murtuza Bharmal, PhD, Associate Director51Bayer HealthCare Pharmaceuticals, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA; 2 Wake Forest University School of Medicine, Winston-Salem, NC, USA; 3 University of Louisville, Louisville, KY, USA; 4 MS Center at HNH, Teaneck, NJ, USA; 5 Quintiles, Inc, Falls Church, VA, USA
OBJECTIVES To measure health-related quality of life (HRQoL) by SF-12 in multiple sclerosis (MS) patients and to compare the SF-12 component scores in MS patients with available US national average scores (norm). METHODS ROBUST is an ongoing multi-center prospective US observational study among MS patients, involving a series of questionnaires completed via a web tool. A battery of items in the patient questionnaire is the SF-12 (Version 2). The ROBUST baseline SF-12 Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) scores were analyzed against US population norms. RESULTS A total of 191 ROBUST participants completed baseline HRQoL assessments and were included in this analysis. The mean (SD) age was 40.6 (11.2) years and a majority were female (81.2%), white (86.9%), married (68.6%) and worked full- or part-time (61.2%). The MCS-12 showed a gradual increase with the level of education. Among the ROBUST population, the mean (SD) scores on PCS-12 [40.64 (11.18)] and MCS-12 [42.54 (11.44)] were significantly lower than the norm [PCS-12 norm: 49.63 (p<0.0001); MCS-12 norm: 49.37 (p<0.0001)]. The PCS-12 [40.11 (11.17)] and MCS-12 [42.42 (11.44)] scores for female MS patients and the PCS-12 [42.92 (11.08)] and MCS-12 [43.05 (11.55)] scores for male MS patients were also significantly lower than the respective norms [all p<0.0001]. Similarly, SF-12 scores for MS patients by age groups [18-24 years; 25-34 years; 35-44 years; 45-54 years; 55-64 years] were significantly lower compared to norms for corresponding age groups [all p<0.001]. Among these age groups within the ROBUST population: PCS-12 scores were lower after 40 years compared to that in younger age group, while MCS-12 scores do not show this same change with age. CONCLUSIONS SF-12 component scores were significantly reduced in the ROBUST population compared to the available national average scores, suggesting a lowering of general HRQoL in MS population.
Conference/Value in Health Info
2009-05, ISPOR 2009, Orlando, FL, USA
Value in Health, Vol. 12, No. 3 (May 2009)
Code
PND24
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Neurological Disorders